The Treatment and Research Group (TRG) on Ebola said on Wednesday it was making progress in the search for a reliable treatment method for the Ebola Virus Disease. The Co-chair of the group, Prof Innocent Ujah, said this in an interview with the News Agency of Nigeria (NAN) in Abuja. Ujah said that the committee had recommended to the Federal Government an experimental drug, known as T705, for use to treat the disease.
He said that the committee also advised the government to approve the commencement of clinical trials on some of the experimental vaccines. We have virtually looked at the experimental drugs and vaccines; it is only one that we have recommended to the Federal Government and that is T705. And then we have the experimental vaccines – the Chinese type and then the Canadian type and then of course there is the one that was brought in by CDC. “We have recommended to government that we need to commence clinical trials on any one of them.”
TRG is a special committee set up by the Federal Government to find better ways of handling the disease. Ujah said that at its last stakeholders’ meeting in Abuja, the committee had identified claims to preventive and curative measures for the virus and was working on them. He said the group would not be hasty in choosing a drug or vaccine for Ebola prevention or treatment, stressing that it would follow acceptable procedures. The co-chair said Nigeria would follow a road map designed by the group of experts in its search for the prevention or cure of the disease.
We have about 35 of those who claim they can either cure or prevent Ebola; and what we are doing now is cataloging those claims and then later verify; it is not something that we can rush into otherwise we will have problems. We don’t want a situation where any of the claimants will be accusing us of being bias, so when we do that we go to the next level. So our road map is to, using the clinical trials, study the experimental drugs and vaccines that are available and we do this in partnership with other countries.